^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Poteligeo (mogamulizumab-kpkc)

    i
    Other names: KM8761, KW 0761, AMG 761, KW-0761
    Company:
    Kyowa Kirin, Swixx BioPharma
    Drug class:
    CCR4 receptor antagonist
    Related drugs:
    Apply
    Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma (NCT00888927)
    Phase 1/2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    04/25/2024
    Initiation :
    05/01/2009
    Primary completion :
    09/01/2012
    Completion :
    09/01/2012
    CD4
    |
    Poteligeo (mogamulizumab-kpkc)
    Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors (NCT02301130)
    Phase 1
    Kyowa Kirin, Inc.
    Completed
    Last update posted :
    04/25/2024
    Initiation :
    11/26/2014
    Primary completion :
    12/08/2017
    Completion :
    03/05/2018
    EGFR • ALK
    |
    ALK rearrangement
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Poteligeo (mogamulizumab-kpkc)
    Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides (NCT05414500)
    Phase 1
    University of Alabama at Birmingham
    Recruiting
    Last update posted :
    12/18/2023
    Initiation :
    05/01/2023
    Primary completion :
    12/30/2024
    Completion :
    06/30/2025
    TNFRSF8
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
    Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (NCT04185220)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/04/2023
    Initiation :
    02/26/2020
    Primary completion :
    11/06/2020
    Completion :
    05/18/2022
    TNFRSF8 • IL15
    |
    Poteligeo (mogamulizumab-kpkc) • rhIL-15
    Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients (NCT02946671)
    Phase 1
    Osaka University
    Completed
    Last update posted :
    03/06/2020
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2020
    Completion :
    03/01/2020
    FOXP3
    |
    Opdivo (nivolumab) • Poteligeo (mogamulizumab-kpkc)
    Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer (NCT02358473)
    Phase 1
    Kyowa Kirin, Inc.
    Completed
    Last update posted :
    11/30/2018
    Initiation :
    01/01/2015
    Primary completion :
    12/01/2016
    Completion :
    12/01/2016
    EGFR • PD-L1 • ALK
    |
    EGFR mutation • ALK rearrangement
    |
    docetaxel • Poteligeo (mogamulizumab-kpkc)
    Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 (NCT01173887)
    Phase 2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    03/30/2017
    Initiation :
    07/01/2010
    Primary completion :
    04/01/2012
    Completion :
    04/01/2012
    CCR4
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • Poteligeo (mogamulizumab-kpkc) • Cymerin (ranimustine) • vindesine
    Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (NCT00920790)
    Phase 2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    03/29/2017
    Initiation :
    06/01/2009
    Primary completion :
    07/01/2010
    Completion :
    11/01/2010
    CCR4
    |
    Poteligeo (mogamulizumab-kpkc)
    Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma (NCT01192984)
    Phase 2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    03/03/2017
    Initiation :
    09/01/2010
    Primary completion :
    05/01/2012
    Completion :
    05/01/2012
    CCR4
    |
    Poteligeo (mogamulizumab-kpkc)
    Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) (NCT01611142)
    Phase 2
    Kyowa Hakko Kirin Pharma, Inc.
    Completed
    Last update posted :
    06/14/2016
    Initiation :
    04/01/2012
    Primary completion :
    05/01/2015
    Completion :
    05/01/2015
    ALK • CCR4
    |
    ALK positive • ALK negative
    |
    Poteligeo (mogamulizumab-kpkc)
    Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. (NCT01929486)
    Phase 1a/1b
    Aichi Medical University
    Unknown status
    Last update posted :
    02/17/2016
    Initiation :
    02/01/2013
    Primary completion :
    06/01/2016
    CCR4
    |
    CCR4 negative
    |
    Poteligeo (mogamulizumab-kpkc)